Payment overview · 2025
General Payments
$243.80
10 reported records · 7 companies
Healthcare provider profile · identity verified
Chad Eugene Boekes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CASTLE ROCK, CO · NPI 1538245816
Verified facts
What the public records show
CMS Open Payments records show Chad Eugene Boekes, M.D. received $243.80 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.35 | 28.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.40 | 18.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.46 | 14.9% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $35.00 | 14.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.76 | 10.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.59 | 7.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.24 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.80 | 9 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 301 | 96 |
| Ezetimibe | Ezetimibe | 283 | 95 |
| Lisinopril | Lisinopril | 241 | 72 |
| Simvastatin | Simvastatin | 230 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 54 |
| Metformin Hcl Er | Metformin Hcl | 150 | 45 |
| Losartan Potassium | Losartan Potassium | 144 | 40 |
| Omeprazole | Omeprazole | 135 | 38 |
| Carvedilol | Carvedilol | 129 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 46 |
| Gabapentin | Gabapentin | 120 | 34 |
| Meloxicam | Meloxicam | 116 | 57 |
| Allopurinol | Allopurinol | 110 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 22 |
| Metformin Hcl | Metformin Hcl | 72 | 19 |
| Montelukast Sodium | Montelukast Sodium | 65 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 62 | 16 |
| Chlorthalidone | Chlorthalidone | 60 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 18 |
| Furosemide | Furosemide | 56 | 19 |
| Eliquis | Apixaban | 54 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 15 |
| Potassium Chloride | Potassium Chloride | 51 | 15 |
| Prednisone | Prednisone | 48 | 30 |
| Fenofibrate | Fenofibrate | 46 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 24 |
| Trazodone Hcl | Trazodone Hcl | 43 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 13 |
| Finasteride | Finasteride | 38 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Niacin Er | Niacin | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 16 |
| Ozempic | Semaglutide | 34 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | 13 |
| Testosterone | Testosterone | 28 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.80 · 10 records | Lilly USA, LLC | EVENITY, MOUNJARO, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, Senza, VOQUEZNA, ZENPEP, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error